Authors' recommendations: Retinoblastoma is the most common primary ocular tumor that occurs in childhood. It is a rapidly developing cancer that arises in the retina of the eye. In children it is the most common primary tumor of the eye. The estimated annual incidence in the United States is approximately 4 per 1 million children < 15 years of age. The annual incidence is 10 to 14 per 1 million in children aged 0 to 4 years. If retinoblastoma metastasizes, it is considered highly lethal, and prognosis with conventional therapy is very poor. Survival rates drop significantly for patients with metastatic disease compared with localized disease; the 5-year disease-free survival is < 10% in those with extraocular disease. Hence, for high-risk patients with metastatic disease, clinicians have used a multimodality treatment approach that incorporates intensive, high-dose chemotherapy and transplantation with autologous stem cell rescue. The goals of such intense, dose-escalation treatment are to eliminate the disease to extend overall survival and disease-free survival, preserve as much vision as possible, and decrease the risk of late complications, particularly second malignancies and severe toxicities.

Project Status: Completed

Year Published: 2011

URL for published report: http://www.hayesinc.com/hayes/crd/?crd=13129

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2011 Winifred S. Hayes, Inc